ACTIVE_NOT_RECRUITING

Continuous Glucose Monitoring for High-Risk Type 2 Diabetes in the Hospital (Cyber GEMS)

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Given the known serious consequences of uncontrolled blood sugars during hospitalization, this research plans to study an alternative seamlessly integrated continuous glucose monitoring (CGM) system in the hospital to test a dynamic and digitized, team-based approach to glucose management in an underserved and understudied, yet high-risk population. A digital dashboard will facilitate real-time, remote monitoring of a large volume of patients simultaneously; automatically identify and prioritize patients for intervention; and will detect any and all potentially dangerous hypoglycemic episodes in a hospital environment. The study will focus on clinical metrics of glucose control and infection that are in-line with patient priorities and US hospital quality initiatives.

Official Title

Continuous Glucose Monitoring for High-Risk Type 2 Diabetes in the Hospital: Cloud-Based Real-Time Glucose Evaluation and Management System (Cyber GEMS)

Quick Facts

Study Start:2022-04-19
Study Completion:2026-01-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT05307237

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Documented previous or current Type 2 Diabetes (T2D) diagnosis as defined by either diagnosis in the chart or an HbA1c \> or = to 6.5% in the last 90 days
  2. * Either on subcutaneous (SQ) insulin orders, or greater than two serum or Point of Care (POC) glucose \> or = 200 mg/dL in most recent 24 hours of admission
  1. * Anticipated length of stay \< 24 hours;
  2. * Current or anticipated ICU placement;
  3. * Does not speak English or Spanish;
  4. * Known allergy to adhesives;
  5. * Current participation in any medication or device research study;
  6. * Pregnant;
  7. * Any other condition that Multiple Principal Investigator (MPI) Philis-Tsimikas or the attending physician deems contraindicated

Contacts and Locations

Principal Investigator

Athena Philis-Tsimikas, MD
PRINCIPAL_INVESTIGATOR
Scripps Whittier Diabetes Institute
Addie Fortmann, PhD
PRINCIPAL_INVESTIGATOR
Scripps Whittier Diabetes Institute

Study Locations (Sites)

Scripps Mercy Hospital
Chula Vista, California, 91910
United States

Collaborators and Investigators

Sponsor: Scripps Whittier Diabetes Institute

  • Athena Philis-Tsimikas, MD, PRINCIPAL_INVESTIGATOR, Scripps Whittier Diabetes Institute
  • Addie Fortmann, PhD, PRINCIPAL_INVESTIGATOR, Scripps Whittier Diabetes Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-04-19
Study Completion Date2026-01-31

Study Record Updates

Study Start Date2022-04-19
Study Completion Date2026-01-31

Terms related to this study

Keywords Provided by Researchers

  • Type 2 Diabetes
  • Hospital
  • Continous Glucose Monitoring

Additional Relevant MeSH Terms

  • Type 2 Diabetes